News

COVID-19 vaccines are currently administered intramuscularly. Studies indicate that intramuscular vaccine administration may not effectively generate antibodies and T cells against SARS-CoV-2 in the respiratory tract mucosa.

Adam Fein, founder of Drug Channels, said the acquisition will allow the company to upgrade its technology, grow the company and provide live and in-person events.

Lipoprotein(a) is a cardiovascular disease risk factor that does not change with diet and exercise. There are no FDA-approved treatments, but two candidates are in phase 3 trials.

We caught up recently with William Shrank, M.D., a longtime member of the Managed Healthcare Executive editorial advisory board. Shrank has held several executive positions with health insurers, most recently Humana. He is now a venture partner with Andreessen Horowitz, a venture capital firm in Menlo Park, California.

The 10 drugs selected by CMS for price negotiation are priced about three times higher in the United States than in other countries, finds a new study by the Commonwealth Fund.

Results point to the benefit of adding Darzalex (daratumumab) to Velcade-Revlimid-dexamethasone triplet therpay, although serious side effects seem be slightly more common when Darzalex is added.

Trial results revealed that tumors shrank in 40% of patients who received the 10-mg dose of tarlatamab and in about 32% of those who received the 100-mg dose.

Results reported in JAMA Psychiatry today show no difference in effectivenes between at-home cranial stimulation and sham treatment.

A subset of natural killer cells may be a potential target for the development of agents protective against MS.

We asked 16 industry professionals what their predictions are for health care in 2024.

Brent Dover is the CEO of Carta Healthcare. He predicts that AI use will reach new heights.

Matt Hollingsworth is the Chief Innovation Officer and Co-Founder of Carta Healthcare. He said there will be a growing need for technology in 2024.

Greg Baker is the CEO of AffirmedRx. He predicts that "transparent PBMs will gain traction" in 2024.

François de Brantes, M.S., MBA is a senior partner at HVC Incentives Advisory Group LLC and a member of Managed Healthcare Executive editorial advisory board. He predicts "price distortions will be revealed" in 2024.

Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.

Melynda Barnes, M.D. is the Chief Medical Officer at Ro. She believes "more people will gain access to GLP-1 inhibitors" in 2024.

Michael Meucci is the CEO of Arcadia. He thinks that EHRs will get an AI makeover.

Maulik P. Purohit, M.D., M.P.H., is the Chief Health Information Officer at the Lehigh Valley Health Network. He believes that "AI will enhance the patient experience" in 2024.

Joerg Schwarz, M.S., is the Senior Director of Healthcare Interoperability at Infor. He believes providers will harness the power of generative AI in 2024.

Brianna Zink, M.S.N, is the Senior Director of Health Care Product Strategy at Infor. She says staff ratios will become a burden in 2024.

This year's top multimedia content includes a video interview with Jennifer Roggenbuck, MS, LGC, of Ohio State University, who addresses the patient journey of ALS.

Laura Kline, MBA, CPCU is the Senior Vice President of Business Development at The Doctors Company. She predicts "APCs will be critical to access care."

Casberg is Vice President of Clinical Pharmacy at IPD Analytics LLC and a member of the Managed Healthcare Executive editorial advisory board. He predicts that "payers will tighten" in 2024.

This year's top HIV articles include one sharing data from a group of researchers from University of Pittsburgh who looked to see if T cell activation is sufficient to drive SIV disease progression.

Kelsay is the President and CEO of the Business Group on Health. She predicts that in 2024, employers will "sound the drug price alarm."

Robert E. White Jr. is the President of The Doctors Company. He believes "social inflation will affect malpractice insurers."

This year's top oncology news included a study that suggested low-fat meals could affect blood concentration levels, and high blood concentration has been associated with a better response to the drug, Alecensa.